Clinical Trial Update: Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pharmacokinetics, pharmacodynamics, safety, and tolerability of fosaprepitant for preventing chemotherapy-induced nausea and v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 2 | Status: COMPLETED | Results posted: 2017-11-21